Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Inhibikase Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18
   10-K10-K10-K10-KS-1/A
Revenue:       
Total revenue  0.13.10.71.14.0
            Total revenue growth  -96.0%343.9%-37.8%-72.2% 
Revenue from Contract with Customer, Product and Service [Extensible List]       
Costs and expenses:       
Research and development  12.011.4   
Selling, general and administrative  6.26.5 4.32.5
    Total costs and expenses  18.317.93.56.86.2
    Loss from operations  -18.1-14.8-1.4-5.7-2.1
            Operating margin  -14686.2%-476.2%-201.1%-507.5%-52.5%
Interest income (expense)  0.10.0   
    Net loss  -18.1-14.8-2.8-5.7-2.2
   
Other comprehensive income, net of tax       
   
Net loss per share - basic  ($0.72)($0.81)($0.35)  
Net loss per share - diluted  ($0.72)($0.81)   
   
Weighted average number of common share - basic  25.218.28.2  
Weighted average number of common share - diluted  25.218.2   

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy